We investigated the efficacy of imatinib and TG101348 using the break point cluster region-c-Abelson (BCR-ABL)-positive cell line and primary CML samples wherein leukemia cells were protected by a feeder cell line (HS-5). Here, ABL1 is linked to chronic myelogenous leukemia, BCR-ABL1 positive.